Abstract
As the global population ages, the prevalence of cognitive impairment among older individuals has been steadily rising. Egypt, like many countries, is grappling with the challenges posed by an aging demographic. Cognitive impairment not only affects the quality of life of older adults but also imposes significant burdens on healthcare systems and societies as a whole. This paper presents findings from the pilot phase of the Longitudinal Study of Egyptian Healthy Aging, known as “AL-SEHA,” shedding light on the intricate relationship between cognitive impairment and noncommunicable diseases (NCDs) in Egypt’s aging population.
KEY MESSAGES
The increasing prevalence of cognitive impairment among the aging population creates a need for a comprehensive understanding of its implications on the individuals’ quality of life
A significant association between cognitive impairment and non-communicable diseases exists and further research can help in the strategic allocation of resources for designing the most effective interventions
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The present work has been supported by the German Academic Exchange Services (DAAD), through the funding program: Higher Education Dialogue with the Muslim World, project (Ageing in the East Mediterranean Region: EMage). This work benefitted from an incentive grant from the World Health Organization (WHO) as part of the WHO Global Noncommunicable Disease (NCD) Platform Young Researchers Programme (Grant reg. № 2022/1256080).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies involving human participants were reviewed and approved by IRB of the American University in Cairo (IRB-AUC). The patients/participants provided their written informed consent to participate in this study. The current work has been approved by the IRB of the American University in Cairo. IRBAUC_ Case# 2021-2022-029
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are fully available and without restrictions
